Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TriSalus Life Sciences ( (TLSI) ) just unveiled an update.
On May 30, 2025, TriSalus Life Sciences announced the appointment of David B. Patience as the new Chief Financial Officer, effective July 1, 2025, following the resignation of James E. Young for personal reasons. This leadership transition is expected to support the company’s growth phase, leveraging Patience’s extensive experience in financial leadership and market analysis, which could enhance TriSalus’s strategic positioning in the oncology sector.
The most recent analyst rating on (TLSI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.
Spark’s Take on TLSI Stock
According to Spark, TipRanks’ AI Analyst, TLSI is a Neutral.
TriSalus Life Sciences is characterized by strong revenue growth and strategic advancements, reflected in the earnings call and corporate events. However, significant financial challenges, including unprofitability and negative equity, weigh heavily on the stock’s overall score.
To see Spark’s full report on TLSI stock, click here.
More about TriSalus Life Sciences
TriSalus Life Sciences is an oncology-focused medical technology company that aims to improve outcomes for patients with solid tumors by integrating innovative delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod. The company offers devices utilizing proprietary Pressure-Enabled Drug Delivery™ technology for hepatic and pancreatic tumors, aiming to enhance therapeutic delivery and reduce side effects.
Average Trading Volume: 49,718
Technical Sentiment Signal: Sell
Current Market Cap: $210.8M
For an in-depth examination of TLSI stock, go to TipRanks’ Stock Analysis page.